信达生物（01801）今日盘中大涨5.90%，引起市场广泛关注。这一显著涨幅主要源于公司发布的中期业绩超出市场预期，以及大华继显发布的积极研究报告。
据大华继显的研究报告显示，信达生物中期收入同比大幅增长50.6%至约60亿元，远超市场预期。调整后纯利达12.1亿元，已超过分析师对其全年调整后纯利的预测。基于这些强劲的财务数据，大华继显上调了信达生物的目标价，从110港元提高至120港元，并维持"买入"评级。
展望未来，信达生物正采用肿瘤治疗和一般生物医学的双引擎增长策略，推出新一轮产品线。公司致力于为全球市场开发领先的管线产品，有望成为全球生物制药市场的重要参与者。大华继显预测信达生物今年收入将同比增长34.8%，并上调了2025至2027年的经调整盈利预测，反映出公司增长潜力强劲。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.